Bright Minds Biosciences (DRUG) Leases (2022 - 2026)
For the quarter ending Q1 2026, Leases changed N/A year-over-year to $52778.4, compared with a TTM value of $52778.4 through Mar 2026, changed N/A, and an annual FY2025 reading of $81359.9, changed N/A over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Leases for 2 consecutive years, with $52778.4 as the latest value for Q1 2026.
- Leases reached $52778.4 in Q1 2026 per DRUG's latest filing, down from $81359.9 in the prior quarter.
- Across five years, Leases topped out at $81359.9 in Q3 2025 and bottomed at $52778.4 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - | 52,778.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,778.45 |
| Dec 31, 2025 | 66,100.30 |
| Sep 30, 2025 | 81,359.87 |
| Jun 30, 2025 | 93,083.59 |
| Mar 31, 2025 | 107,682.66 |
| Dec 31, 2024 | 126,700.29 |
| Sep 30, 2024 | 86,249.60 |
| Jun 30, 2024 | 8,828.52 |
| Mar 31, 2024 | 22,402.91 |
| Dec 31, 2023 | 35,478.07 |
| Sep 30, 2023 | 49,539.48 |
| Jun 30, 2023 | 62,924.84 |
| Mar 31, 2023 | 75,920.96 |
| Dec 31, 2022 | 88,957.62 |
| Sep 30, 2022 | 106,472.68 |